BioSpace News Archive

Guardant Health applauds Medicare for changes it made to a final National Coverage Decision (NCD) that ensure continued access to molecular diagnostics for Medicare beneficiaries with advanced cancer.

AMPAC Fine Chemicals (AFC) today announced that Lee Gauthier has joined AFC’s executive team as Vice President of Operations responsible for manufacturing across all AFC’s sites.

New 5 CD platform combines Gyrolab immunoassay technology with expanded software to optimize time to results and sample capacity while simplifying workflows; Gyrolab xPand will be showcased on March 19-22 at BPI West in San Francisco and April 9-13 at WRIB in Philadelphia

Health Plan reports operating gain and 94% commercial membership retention as government business achieves turnaround; Allegheny Health Network revenue growth of nearly 40% since formation [19-March-2018] Highmark Health posts $1.1 billion in consolidated net income, affirms $1 billion investment in value-based, community-focused strategy

The program will also deliver updates from American Society of Hematology 2017

Severe traumatic brain injury in children was associated with increased risk for later onset of attention-deficit/hyperactivity (ADHD) up to about seven years after injury, according to a study in JAMA Pediatrics.

CANTEL MEDICAL CORP. (NYSE: CMD) announced today that Jorgen B. Hansen, President and CEO, will be participating in an analyst-led fireside chat with investors at the 17th Annual Needham & Company Healthcare Conference at the Westin Grand Central Hotel in New York, on Tuesday, March 27 at 4:30 p.m. ET.

Three industry leaders join company ranks to drive genomic discovery

Biotheranostics, Inc., reports publication in JCO Precision Oncology of a prospective, multi-institutional, clinical utility study evaluating the impact of CancerTYPE ID on final diagnosis and treatment in patients with an unknown or unclear metastatic cancer diagnosis.

Pfizer Inc. and Astellas Pharma, Inc. announced that a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) has been accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA).